Xenitra (ASX:XEN) reported a preliminary unaudited sales increase of over 300% for the third quarter.
The Sydney-based firm, which operates a pioneering blockchain-tokenised sales ecosystem across Asia, saw its Q3 revenue climb to $8.3 million, marking a material leap from the previous quarter’s performance.
The company’s growth trajectory has been particularly robust within the fast-moving consumer goods, nutraceuticals, and over-the-counter medicine sectors.
According to the announcement, this recent surge was primarily fuelled by the Nutritionals division, bolstered by a $30 million partnership with the Rockcheck Group to distribute Danone products.
The expansion leverages Xenitra’s established distribution network, which encompasses B2B wholesale, traditional retail, and major e-commerce platforms throughout the Asian market.
Since 2024, the company has successfully facilitated over $70 million in total sales.
A month-by-month analysis of the Q3 data reveals a consistent upward trend. Sales commenced in January at approximately $1.6 million, grew to over $2.6 million in February, and peaked in March at roughly $4.3 million.
The steady monthly acceleration underscores the successful integration of the Rockcheck partnership and the increasing scalability of Xenitra’s blockchain-integrated supply chain.
At the time of reporting, Xenitra's share price was $0.0040.